As shown in Figures S2–S5, most clinical features, including age, sex, tumor stage, microsatellite instability, adjuvant chemotherapy, and KRAS mutation, were not significantly different between the high and low-risk groups in all four cohorts. This evidence concerns the gene KRAS and neoplasm.